Regeneron/$REGN
1D1W1MYTD1Y5YMAX
Capital at risk
About Regeneron
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
- Ticker
- $REGN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 15,410
- Headquarters
- Tarrytown, United States
- Website
- www.regeneron.com
Regeneron Metrics
BasicAdvanced
$79B
19.62
$40.43
0.19
$3.70
0.47%
Price and volume
Market cap
$79B
Beta
0.19
52-week high
$859.34
52-week low
$541.00
Average daily volume
724K
Dividend rate
$3.70
Financial strength
Current ratio
3.335
Quick ratio
2.633
Long term debt to equity
8.535
Total debt to equity
8.535
Dividend payout ratio (TTM)
8.74%
Interest coverage (TTM)
75.34%
Profitability
EBITDA (TTM)
4,702.4
Gross margin (TTM)
44.46%
Net profit margin (TTM)
27.86%
Operating margin (TTM)
26.87%
Effective tax rate (TTM)
16.21%
Revenue per employee (TTM)
$1,010,000
Management effectiveness
Return on assets (TTM)
6.53%
Return on equity (TTM)
14.04%
Valuation
Price to earnings (TTM)
19.619
Price to revenue (TTM)
5.277
Price to book
2.51
Price to tangible book (TTM)
2.62
Price to free cash flow (TTM)
22.931
Free cash flow yield (TTM)
4.36%
Free cash flow per share (TTM)
34.593
Dividend yield (TTM)
0.47%
Forward dividend yield
0.47%
Growth
Revenue change (TTM)
9.29%
Earnings per share change (TTM)
1.91%
3-year revenue growth (CAGR)
7.03%
10-year revenue growth (CAGR)
12.82%
3-year earnings per share growth (CAGR)
2.25%
10-year earnings per share growth (CAGR)
20.22%
What the Analysts think about Regeneron
Analyst ratings (Buy, Hold, Sell) for Regeneron stock.
Analyst projections of the future price of Regeneron stock.
Bulls say / Bears say
Regeneron’s Q2 2026 revenue rose 17% year-on-year to $4.29 billion and non-GAAP EPS of $14.29 per share surpassed forecasts, marking a second consecutive quarter of double-digit growth. (Reuters)
Global net sales of Dupixent surged 38% to about $6 billion in Q2 2026, driven by robust demand across immunology indications under its partnership with Sanofi. (Reuters)
In Q1 2026, Regeneron repurchased $803 million of common stock and authorized an additional $3.0 billion share repurchase program, underscoring management’s commitment to returning capital to shareholders. (Reuters)
Regeneron trimmed its full-year 2026 GAAP gross margin guidance to 77%–78% from a prior 79%–80%, flagging margin headwinds from manufacturing disruptions and cost pressures. (Reuters)
Under a Trump administration drug pricing deal announced in April 2026, Regeneron agreed to slash Medicaid prices for its current and future medicines in exchange for tariff exemptions, potentially limiting pricing flexibility for its high-margin products over the next three years. (Reuters)
Regeneron’s lower-dose Eylea U.S. sales fell amid continued competitive pressures and patient transitions to the 8-mg high-dose version, highlighting growing biosimilar and market share challenges in its ophthalmology franchise. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 26 Aug 2026.
Regeneron Financial Performance
Revenues and expenses
Regeneron Earnings Performance
Company profitability
Upcoming events
No upcoming events
Regeneron News
AllArticlesVideos
MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
Business Wire16 hours ago
REGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
Newsfile Corp3 days ago
1 WEEK REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 Deadline
Newsfile Corp4 days ago
Funds containing Regeneron
AllUSDGBPEUR
Fund name | Fund size | $REGN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 5.02% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 5.02% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 1.15% |
iShares Ageing Population€AGED | €822M | 0.53% |
iShares MSCI USA Islamic$ISDU | $594M | 0.47% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.